Name
tnfa_r1_pg_ml
Label
Tumor necrosis factor-alpha receptor-1
Units
picograms per milliliter
Type
numeric
Visit number vs Tumor necrosis factor-alpha receptor-1
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Baseline | 317 | 1,589.6 | ± 575.6 | 1,442.7 | 80.1 | 4,258.9 | 1 | 318 |
Follow-up | 295 | 1,638.7 | ± 623.2 | 1,448.5 | 734.7 | 4,510.6 | 6 | 301 |
Treatment Arm vs Tumor necrosis factor-alpha receptor-1
Baseline
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 317 | 1,589.6 | ± 575.6 | 1,442.7 | 80.1 | 4,258.9 | 1 | 318 |
Healthy Lifestyles and Sleep Education - control arm (HLSE) | 106 | 1,639.5 | ± 626.0 | 1,496.6 | 733.1 | 3,899.7 | - | 106 |
Healthy Lifestyles and Sleep Education + (supplemental nocturnal) Oxygen - oxygen arm (HLSE-O) | 105 | 1,612.0 | ± 602.7 | 1,459.7 | 80.1 | 4,258.9 | 1 | 106 |
Healthy Lifestyles and Sleep Education + Positive airway pressure treatment - CPAP arm (HLSE-P) | 106 | 1,517.6 | ± 487.1 | 1,416.4 | 381.0 | 3,126.1 | - | 106 |
Treatment Arm vs Tumor necrosis factor-alpha receptor-1
Follow-up
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 295 | 1,638.7 | ± 623.2 | 1,448.5 | 734.7 | 4,510.6 | 6 | 301 |
Healthy Lifestyles and Sleep Education - control arm (HLSE) | 99 | 1,719.9 | ± 722.9 | 1,527.3 | 855.6 | 4,510.6 | 1 | 100 |
Healthy Lifestyles and Sleep Education + (supplemental nocturnal) Oxygen - oxygen arm (HLSE-O) | 98 | 1,617.7 | ± 562.4 | 1,462.6 | 857.6 | 3,833.3 | 3 | 101 |
Healthy Lifestyles and Sleep Education + Positive airway pressure treatment - CPAP arm (HLSE-P) | 98 | 1,577.8 | ± 567.6 | 1,408.4 | 734.7 | 3,949.1 | 2 | 100 |
Age category vs Tumor necrosis factor-alpha receptor-1
Baseline
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 317 | 1,589.6 | ± 575.6 | 1,442.7 | 80.1 | 4,258.9 | 1 | 318 |
45-54 years | 53 | 1,461.3 | ± 587.2 | 1,356.8 | 80.1 | 3,899.7 | - | 53 |
55-64 years | 139 | 1,524.4 | ± 543.2 | 1,418.7 | 381.0 | 3,858.3 | - | 139 |
65 years or older | 125 | 1,716.7 | ± 586.0 | 1,595.5 | 824.8 | 4,258.9 | 1 | 126 |
Age category vs Tumor necrosis factor-alpha receptor-1
Follow-up
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 295 | 1,638.7 | ± 623.2 | 1,448.5 | 734.7 | 4,510.6 | 5 | 300 |
45-54 years | 46 | 1,526.9 | ± 549.6 | 1,356.7 | 938.7 | 4,124.8 | 3 | 49 |
55-64 years | 125 | 1,536.8 | ± 571.4 | 1,375.7 | 842.1 | 4,040.1 | 2 | 127 |
65 years or older | 124 | 1,783.0 | ± 672.8 | 1,618.8 | 734.7 | 4,510.6 | - | 124 |
Gender of the participant vs Tumor necrosis factor-alpha receptor-1
Baseline
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 317 | 1,589.6 | ± 575.6 | 1,442.7 | 80.1 | 4,258.9 | 1 | 318 |
Female | 83 | 1,659.9 | ± 681.3 | 1,492.5 | 80.1 | 4,258.9 | 1 | 84 |
Male | 234 | 1,564.7 | ± 532.6 | 1,426.1 | 733.1 | 3,899.7 | - | 234 |
Gender of the participant vs Tumor necrosis factor-alpha receptor-1
Follow-up
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 295 | 1,638.7 | ± 623.2 | 1,448.5 | 734.7 | 4,510.6 | 6 | 301 |
Female | 78 | 1,735.0 | ± 722.7 | 1,456.2 | 842.1 | 4,040.1 | 1 | 79 |
Male | 217 | 1,604.1 | ± 581.3 | 1,447.2 | 734.7 | 4,510.6 | 5 | 222 |
Race of the participant vs Tumor necrosis factor-alpha receptor-1
Baseline
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 316 | 1,586.5 | ± 573.8 | 1,442.1 | 80.1 | 4,258.9 | 1 | 317 |
White | 256 | 1,563.4 | ± 516.5 | 1,448.3 | 80.1 | 3,899.7 | - | 256 |
American Indian or Alaskan Native | 2 | 1,633.1 | ± 735.1 | 1,633.1 | 1,113.3 | 2,152.8 | - | 2 |
Black or African American | 42 | 1,740.4 | ± 847.6 | 1,397.1 | 716.3 | 4,258.9 | 1 | 43 |
Asian | 6 | 1,354.4 | ± 219.5 | 1,392.9 | 986.6 | 1,601.3 | - | 6 |
Native Hawaiian or other Pacific islander | 1 | 1,898.2 | - | 1,898.2 | 1,898.2 | 1,898.2 | - | 1 |
Other | 4 | 1,812.2 | ± 872.5 | 1,641.8 | 952.2 | 3,012.8 | - | 4 |
Multiple | 5 | 1,490.5 | ± 582.7 | 1,356.8 | 1,011.5 | 2,484.2 | - | 5 |
Race of the participant vs Tumor necrosis factor-alpha receptor-1
Follow-up
N | Mean | StdDev | Median | Min | Max | Unknown | Total | |
---|---|---|---|---|---|---|---|---|
Total | 294 | 1,633.9 | ± 618.8 | 1,447.9 | 734.7 | 4,510.6 | 5 | 299 |
White | 238 | 1,617.2 | ± 561.7 | 1,480.0 | 734.7 | 4,510.6 | 3 | 241 |
American Indian or Alaskan Native | 2 | 1,670.8 | ± 424.4 | 1,670.8 | 1,370.8 | 1,970.9 | - | 2 |
Black or African American | 39 | 1,767.4 | ± 900.7 | 1,346.0 | 842.1 | 4,040.1 | 2 | 41 |
Asian | 6 | 1,339.3 | ± 215.9 | 1,362.9 | 1,006.1 | 1,593.9 | - | 6 |
Native Hawaiian or other Pacific islander | 1 | 1,965.4 | - | 1,965.4 | 1,965.4 | 1,965.4 | - | 1 |
Other | 3 | 2,056.3 | ± 1,058.8 | 1,616.3 | 1,288.4 | 3,264.2 | - | 3 |
Multiple | 5 | 1,406.7 | ± 663.2 | 1,351.9 | 858.8 | 2,520.5 | - | 5 |